Browse the evidence

Multi-agonists targeting GLP-1R along with other receptors (GIPR, GCGR) demonstrate superior weight loss and glycemic control compared to single GLP-1R agonists.

Newer 'multi-agonist' diabetes and obesity drugs (like Tirzepatide) target multiple hormone receptors simultaneously. This approach often leads to greater weight loss and better blood sugar control than older single-target GLP-1 drugs. They are taken as weekly injections and are approved for both Type 2 Diabetes and Obesity.

The thermic effect of food (TEF) varies significantly by macronutrient composition, with protein eliciting a thermic effect at least three times higher than isocaloric carbohydrates, while fat elicits a much lower thermic effect.

Eating protein costs more energy to digest than carbs or fat. Prioritizing protein in your diet can slightly increase your daily energy expenditure through the thermic effect of food.

A multifactorial approach targeting glucose, blood pressure, lipids, and lifestyle simultaneously is the most effective strategy for preventing diabetes complications.

To prevent serious health issues, you need to manage your blood sugar, blood pressure, and cholesterol together, not just one. This involves lifestyle changes like eating well, exercising 150 minutes a week, and losing weight, often supported by medications. This combined approach is proven to be the best way to protect your heart and kidneys.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to selective GLP-1 agonists (semaglutide) and basal insulins (degludec, glargine) in patients with type 2 diabetes.

Tirzepatide is a once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1) to improve how your body handles sugar and fat. Clinical trials show it lowers blood sugar and reduces body weight more effectively than standard diabetes medications like insulin or other GLP-1 drugs like semaglutide. It is prescribed for adults with type 2 diabetes or obesity, starting at a low dose to minimize stomach upset, and increasing over time. It is not suitable for people with a specific family history of thyroid cancer.

Tirzepatide induces significant weight loss (up to 20.4% with 15mg dose) in individuals with overweight or obesity, comparable to effects observed with bariatric surgery.

For individuals with obesity, tirzepatide offers a non-surgical path to significant weight loss. In clinical trials, the highest dose resulted in an average loss of over 20% of body weight, which is comparable to the results typically seen with bariatric surgery. This makes it a powerful alternative for those who cannot undergo or prefer to avoid surgery.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) produce significant weight loss in adults with obesity, primarily through central appetite suppression and delayed gastric emptying, with efficacy varying by specific agent and dose.

GLP-1 agonists like semaglutide (2.4mg weekly) and liraglutide (1.8mg daily) are highly effective for weight loss, significantly outperforming lifestyle changes alone. They work by slowing digestion and reducing hunger signals in the brain. While effective, they require chronic use to maintain weight loss, and side effects like nausea are common.

Dual incretin agonists (GLP-1/GIP) such as tirzepatide demonstrate superior weight loss efficacy compared to single GLP-1 agonists.

Tirzepatide (15mg weekly) is a dual-acting drug (GLP-1/GIP) that produces greater weight loss (~21%) than single-acting GLP-1 drugs. It is currently approved for type 2 diabetes and under review for obesity. It requires weekly injection and medical supervision.

Switching from saturated and trans fats to unsaturated fats (MUFAs and PUFAs) in the diet causally reduces plasma LDL particle concentration, thereby reducing the risk of atherosclerotic cardiovascular disease (ASCVD).

To lower your risk of heart disease, focus on swapping the types of fat you eat. Replace saturated fats (found in butter, fatty meats, full-fat dairy) and trans fats with unsaturated fats (found in olive oil, nuts, seeds, and fatty fish). This substitution lowers LDL cholesterol, which is a primary driver of heart disease. You don't need to eliminate fat; just choose higher-quality sources.

Once-weekly 2.4 mg semaglutide produces significant weight loss and cardiometabolic improvements in adults with obesity, regardless of whether the treatment is combined with standard or very intensive lifestyle interventions.

Take 2.4 mg of semaglutide once weekly, starting with a low dose (0.25 mg) and increasing every 4 weeks to minimize side effects. While you should still eat healthy and exercise, do not expect lifestyle changes to significantly boost weight loss beyond what the medication provides. The drug itself is the primary driver of weight loss.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce substantial weight loss (up to 20%) by acting on CNS neural circuits, specifically the dorsal vagal complex.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, often resulting in 10-20% body weight reduction. They work by acting on brain circuits that control appetite. You must take them chronically, as stopping leads to weight regain. Side effects like nausea are common but manageable.

An intensive lifestyle intervention (ILS) focused on weight loss and increased physical activity reduces the incidence of type 2 diabetes by 58% compared to placebo in high-risk adults with prediabetes, with effects sustained over 21 years.

To significantly lower your risk of developing type 2 diabetes, focus on losing 7% of your body weight and getting at least 150 minutes of moderate physical activity per week. This lifestyle approach is proven to be more effective than medication (metformin) for preventing diabetes in high-risk individuals, with benefits lasting for decades.

Metformin (850 mg twice daily) reduces the incidence of type 2 diabetes by 31% compared to placebo in high-risk adults, with greater efficacy in individuals with a BMI >= 35 kg/m2 and fasting glucose 110–125 mg/dL.

If you are at high risk for type 2 diabetes, metformin (850 mg twice daily) can reduce your risk by 31%. However, it is most effective if you have a BMI of 35 or higher or a fasting glucose between 110-125 mg/dL. Lifestyle changes remain more effective overall.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce 15–25% mean weight loss and reduce cardiovascular events by 20% and type 2 diabetes incidence by 72%.

If you have obesity or overweight with a related health condition, GLP-1 medications like semaglutide (Wegovy) or tirzepatide (Zepbound) are currently the most effective pharmacological treatments, offering 15-25% weight loss and significant cardiovascular benefits. These require weekly injections (or oral forms for some) and work best when combined with a modest caloric deficit and regular exercise. Be aware of potential gastrointestinal side effects and the need for long-term management, as stopping the medication often leads to weight regain.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves higher mean weight loss (up to 20.9%) than selective GLP-1 agonists.

Tirzepatide (Zepbound) is a once-weekly injection that targets both GIP and GLP-1 receptors, resulting in an average 20.9% weight loss over 72 weeks, which is higher than semaglutide. It is indicated for adults with obesity or overweight with comorbidities. Like other GLP-1 agonists, it requires lifestyle changes and may cause gastrointestinal side effects. Access may be limited by cost and insurance coverage.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces HbA1c (by 1.7–2.4%) and body weight (up to 22.5%) in patients with type 2 diabetes compared to placebo, semaglutide, and insulin therapies.

Tirzepatide is a once-weekly injection for type 2 diabetes that significantly lowers blood sugar and promotes substantial weight loss. It starts at a low dose (2.5 mg) to minimize stomach issues, then increases every 4 weeks up to 15 mg. It is more effective for weight loss and A1C reduction than insulin or semaglutide in head-to-head trials. Common side effects are gastrointestinal (nausea, diarrhea) but are usually mild. It is contraindicated for those with a history of medullary thyroid carcinoma.

Lifestyle modifications, specifically Mediterranean diet and moderate aerobic exercise, are the cornerstone for managing insulin resistance and improving cardiovascular outcomes.

Start with the basics: eat a Mediterranean-style diet (lots of veggies, whole grains, healthy fats) and aim for 150 minutes of moderate exercise per week. This is the most effective way to improve insulin sensitivity and protect your heart, serving as the foundation for any medication you might take.

GLP-1 receptor agonists (GLP-1 RAs) produce significant weight loss (7–24%) and HbA1c reductions (1.5–2.0%) through pleiotropic mechanisms including enhanced mitochondrial function, anti-inflammatory actions, and improved cellular quality control.

GLP-1 medications are highly effective for weight loss and blood sugar control. They work through multiple biological pathways, not just hunger suppression. Newer oral versions exist for those who prefer pills over injections. Consult a doctor to determine the right agent and dose for your specific health profile.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide) reduce major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease, as well as in non-diabetic patients with obesity and cardiovascular disease.

If you have Type 2 Diabetes and heart disease, or obesity and heart disease, GLP-1 agonists like semaglutide or liraglutide are proven to significantly lower your risk of heart attack, stroke, and heart-related death. This benefit exists alongside blood sugar control. Discuss with your doctor if you are a candidate, considering the cost and injection/oral delivery options.

Contemporary NuSH anti-obesity medications (semaglutide, tirzepatide) produce significantly greater weight loss than intensive lifestyle interventions alone.

If you are struggling to lose weight despite strict diet and exercise, it may be biological, not behavioral. AOMs can produce 15%+ weight loss, far exceeding what lifestyle changes alone typically achieve. Consult a doctor to see if you are a candidate.

Tirzepatide (5-15 mg weekly) significantly improves glycemic control (HbA1c reduction of 1.87-2.58%) and induces substantial weight loss (up to 13.9 kg) in patients with type 2 diabetes, outperforming GLP-1 receptor agonists (semaglutide, dulaglutide) and basal insulin (degludec, glargine).

If you have type 2 diabetes, Tirzepatide is a once-weekly injection that significantly lowers blood sugar (HbA1c) and helps you lose a substantial amount of weight, often more effectively than other common diabetes medications like semaglutide or basal insulin. It works by mimicking two gut hormones (GIP and GLP-1) to improve how your body handles glucose and fat. You start at a low dose (2.5 mg) and increase it every few weeks to minimize stomach upset, which is common but usually temporary. It is approved for adults with T2DM, including those who are insulin-dependent.

Subcutaneous semaglutide 2.4 mg administered once weekly, combined with lifestyle interventions, produces sustained, clinically significant weight loss (average 14.9% reduction from baseline) in adults with obesity or overweight.

If you have obesity or are overweight, a once-weekly injection of semaglutide (2.4 mg) combined with lifestyle changes can lead to significant, sustained weight loss, averaging nearly 15% of your body weight. While you may experience mild, temporary nausea, the weekly schedule is designed to improve adherence compared to daily treatments. This option is particularly relevant if other GLP-1 agonists like liraglutide have not provided sufficient results.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, significantly reduces HbA1c and body weight in patients with type 2 diabetes and obesity, demonstrating superior efficacy compared to placebo, semaglutide, and basal insulin.

Tirzepatide is a once-weekly injection that activates two gut hormones (GLP-1 and GIP) to lower blood sugar and promote significant weight loss. It is approved for Type 2 Diabetes and Obesity. Clinical trials show it lowers HbA1c more effectively than other common diabetes drugs and leads to greater weight loss than GLP-1-only drugs like semaglutide. Start with a low dose (2.5 mg) and increase slowly to minimize stomach upset. It requires a prescription and lifestyle changes (diet/exercise).

Second-generation incretin receptor agonists (GLP-1 RAs like semaglutide and liraglutide, and dual GLP-1/GIP agonist tirzepatide) significantly reduce blood pressure and promote weight loss in obesity-related hypertension, outperforming first-generation anti-obesity drugs.

For obesity-related hypertension, second-generation incretin receptor agonists (GLP-1 RAs) like semaglutide (2.4 mg weekly) or liraglutide (3 mg daily) are the most effective pharmacological treatments for lowering blood pressure and promoting weight loss. They significantly outperform older anti-obesity drugs. These medications should be integrated with lifestyle changes (diet and exercise) and are particularly effective in non-diabetic obese patients, though they also benefit those with type 2 diabetes.

GLP-1 receptor agonists (semaglutide, liraglutide) produce significantly greater weight loss than lifestyle modifications alone and are superior to older agents like orlistat and liraglutide (1.8mg).

If lifestyle changes alone haven't worked, GLP-1 agonists like semaglutide are highly effective. They work by mimicking a hormone that controls hunger. You take a weekly injection. Expect some stomach issues initially, but they often subside. These drugs are significantly more effective than older options like orlistat.